EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeted glycan degradation potentiates cellular immunotherapy for solid tumors

Jicheng Wu, Xudong Wang, Yuqiao Huang, Yunjing Zhang, Siyu Su, Hao Shou, Haoran Wang, Jin Zhang, Ben Wang iD

Proceedings of the National Academy of Sciences · 19.09.2023 · 120 (38)

DOI: 10.1073/pnas.2300366120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 11.09.2023. Verfasst von Jicheng Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejia…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Key Research and Development Program of China, MOST | National Natural Science Foundation of China, Foundation for Innovative Research Groups of the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune cell–based cancer therapies, such as chimeric antigen receptor T (CAR-T)-cell immunotherapy, have demonstrated impressive potency against hematological tumors. However, the efficacy of CAR-T cells against solid tumors remains limited. Herein, we designed tumor-targeting molecule–sialidase conjugates that potently and selectively stripped different sialoglycans from a variety of cancer cells. Desialylation enhanced induced pluripotent stem cell–derived chimeric antigen receptor–macrophage (CAR-iMac) infiltration and activation. Furthermore, the combination of cancer cell desialylation and CAR-iMac adoptive cellular therapy exerted a dramatic therapeutic effect on solid tumors and significantly prolonged the survival of tumor-bearing mice; these effects were mainly dependent on blockade of the checkpoint composed of sialic acid–binding immunoglobulin-like lectin (Siglec)-5 and Siglec-10 on the macrophages, and knockout of the glycoimmune checkpoint receptors could construct a CAR-iMac cell with stronger anticancer activity. This strategy that reverts the immune escape state (“cold tumor”) to a sensitive recognition state (“hot tumor”) has great significance for enhancing the effect of cellular immunotherapy on solid tumors. Therefore, desialylation combined with CAR-iMac cellular immunotherapy is a promising approach to enhance treatment with cellular immunotherapy and expand the valid indications among solid tumors, which provides inspiration for the development of cellular immunotherapies with glycoimmune checkpoint inhibition for the treatment of human cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeoplasmsHumansAnimalsMiceImmunotherapyCarbohydrate MetabolismPolysaccharides

Stichwörter der Autor:innen

Siglecscellular immunotherapydesialylationsialic acidsolid tumors

Substanzen

Receptors, Chimeric AntigenPolysaccharides

Autor:innen und Institutionen

  • Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
  • Institute of Translational Medicine, Zhejiang University, Hangzhou 310029, China.
  • Cancer Center, Renmin Hospital of Wuhan University, Wuhan 430060, China.
  • Center for Stem Cell and Regenerative Medicine, Department of Basic Medical Sciences, and The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
  • Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou 311121, China.
  • Ultrasonic Department, Renmin Hospital of Wuhan University, Wuhan 430060, China.

ORCID-Profile: Ben Wang

Förderung

  • MOST | National Key Research and Development Program of China
  • MOST | National Natural Science Foundation of China
  • Foundation for Innovative Research Groups of the National Natural Science Foundation of China
  • MOST | NSFC | NSFC-Zhejiang Joint Fund | 浙江省科学技术厅 | Natural Science Foundation of Zhejiang Province
  • MOE | Fundamental Research Funds for the Central Universities
  • Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang

Zitieren

APA

Wu, J., Wang, X., Huang, Y., Zhang, Y., Su, S., Shou, H., Wang, H., Zhang, J., & Wang, B. (2023). Targeted glycan degradation potentiates cellular immunotherapy for solid tumors. Proceedings of the National Academy of Sciences, 120(38). https://doi.org/10.1073/pnas.2300366120

Vancouver

Wu J, Wang X, Huang Y, Zhang Y, Su S, Shou H, et al. Targeted glycan degradation potentiates cellular immunotherapy for solid tumors. Proceedings of the National Academy of Sciences. 2023;120(38). doi:10.1073/pnas.2300366120

BibTeX
@article{Wu2023,
  author = {Wu, Jicheng and Wang, Xudong and Huang, Yuqiao and Zhang, Yunjing and Su, Siyu and Shou, Hao and Wang, Haoran and Zhang, Jin and Wang, Ben},
  title = {Targeted glycan degradation potentiates cellular immunotherapy for solid tumors},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  volume = {120},
  number = {38},
  doi = {10.1073/pnas.2300366120}
}
Kostenlos starten →